Compass study result validates industry’s hope to find alternative treatments for mental health
Marijuana Stocks, Finance, & InvestingUncategorized November 20, 2021 MJ Shareholders
Psychedelic companies feel that Compass Pathways results validate efforts to develop next-generation medicine for treating mental health issues
Hours after psychedelic leader Compass Pathways (NASDAQ:CMPS) announced Phase IIb results from the largest modern study on a psychedelic substance, the stocks of most psychedelic companies holistically took a nosedive despite generally positive results.
Peter Theil-backed Compass published data revealing that a strong dose of its Comp360 medication (a psiloCybin (NEO:CYBN)-derivative in a crystalline form) helped reduce depression in patients suffering from the treatment-resistant mental health issue.
While overall positive, results indicated that 179 of the 233 participants in the trial experienced treatment-emergent side effects. Compass, however, said that except for 12 patients, the rest experienced mild adverse events like headache, nausea, fatigue, and insomnia.
Read More
MJ Shareholders
MJShareholders.com is the largest dedicated financial network and leading corporate communications firm serving the legal cannabis industry. Our network aims to connect public marijuana companies with these focused cannabis audiences across the US and Canada that are critical for growth: Short and long term cannabis investors Active funding sources Mainstream media Business leaders Cannabis consumers
